KALA BIO, Inc.
KALA- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001479419
No open-market purchases or sales by KALA BIO, Inc. insiders were filed in the last 90 days; 15 institutions reported holding it in 13F filings for Q2 2026, worth $1.21M in total; no superinvestor holds it.
Q1 2023 vs. Q4 2022
How the institutions holding KALA BIO, Inc. changed between Q4 2022 and Q1 2023.
All holders in Q1 2023All holders in Q4 2022
| Measure | Q4 2022 | Q1 2023 | Change |
|---|---|---|---|
| Holders | 30 | 26 | −4 |
| Shares | 336.2K | 319.5K | −16.7K (−5.0%) |
| Value | $12.8M | $4.81M | −$8.01M (−62.5%) |
New holders (2)
Institutions that held KALA BIO, Inc. at the end of Q1 2023 but not at the end of Q4 2022.
| Institution | Shares | Value | % of portfolio |
|---|---|---|---|
| Northwestern Mutual Wealth Management Co | 5 | $75 | 0.00% |
| Bank of New Hampshire | 1 | $15 | 0.00% |
Sold out (6)
Institutions that held KALA BIO, Inc. at the end of Q4 2022 and filed for Q1 2023 without it.
| Institution | Shares, Q4 2022 | Value, Q4 2022 |
|---|---|---|
| Clear Street LLC | 49,390 | $1.88M |
| Renaissance Technologies LLC | 10,592 | $404.0K |
| State Street Corp | 9,986 | $381.0K |
| Geode Capital Management, LLC | 8,936 | $340.0K |
| Two Sigma Securities, LLC | 6,517 | $248.6K |
| MCF Advisors LLC | 230 | $8.77K |